Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts ...

Research analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the ...

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

FDIS follows the MSCI USA IMI Consumer Discretionary Index. It invests in large-, mid- and small-cap stocks and carries an ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of ...

Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies. Click here to find out why I ...

Day One Biopharmaceuticals focuses on pediatric cancer treatments. Read more about the biotech's therapies and its prospects ...

Health care stocks trended downward for most of 2024, significantly underperforming broader stock indexes. Over the past year, the S&P 500 Health Care index rose by only 0.

Cathie Wood-led Ark Invest made significant trades involving PLTR, ARKB, and QSI. The PLTR trade sold shares worth $1.6 million, aligning with Ark's trend of reducing their position in the hot AI ...